NO972732D0 - Karsinombehandling - Google Patents

Karsinombehandling

Info

Publication number
NO972732D0
NO972732D0 NO972732A NO972732A NO972732D0 NO 972732 D0 NO972732 D0 NO 972732D0 NO 972732 A NO972732 A NO 972732A NO 972732 A NO972732 A NO 972732A NO 972732 D0 NO972732 D0 NO 972732D0
Authority
NO
Norway
Prior art keywords
karsinombehandling
carcinomas
inducer
prevention
conjunction
Prior art date
Application number
NO972732A
Other languages
English (en)
Other versions
NO972732L (no
NO318587B1 (no
Inventor
Lawrence Sterling Young
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of NO972732L publication Critical patent/NO972732L/no
Publication of NO972732D0 publication Critical patent/NO972732D0/no
Publication of NO318587B1 publication Critical patent/NO318587B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
NO19972732A 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose NO318587B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425060.2A GB9425060D0 (en) 1994-12-13 1994-12-13 Carcinoma treatment
PCT/GB1995/002807 WO1996018413A1 (en) 1994-12-13 1995-12-01 Carcinoma treatment

Publications (3)

Publication Number Publication Date
NO972732L NO972732L (no) 1997-06-13
NO972732D0 true NO972732D0 (no) 1997-06-13
NO318587B1 NO318587B1 (no) 2005-04-11

Family

ID=10765814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19972732A NO318587B1 (no) 1994-12-13 1997-06-13 Anvendelse av en CD40-reseptorbinder for fremstilling av et medikament for forebyggelse av epitelcelleproliferasjon eller for behandling av karsinomer i epitelcellesystemer, samt for forsterkning av mottakeligheten til neoplastiske epitelceller for anti-neoplastisk medikamentindusert apotose

Country Status (12)

Country Link
EP (1) EP0806963B1 (no)
JP (1) JP4076230B2 (no)
AT (1) ATE203676T1 (no)
AU (1) AU691996B2 (no)
CA (1) CA2207779C (no)
DE (1) DE69522012T2 (no)
FI (1) FI118918B (no)
GB (1) GB9425060D0 (no)
MX (1) MX9704372A (no)
NO (1) NO318587B1 (no)
NZ (1) NZ296161A (no)
WO (1) WO1996018413A1 (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
GB0025132D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Method
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1680141T3 (da) * 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
JP5027804B2 (ja) 2005-05-26 2012-09-19 シアトル ジェネティクス，インコーポレーテッド ヒト化抗ｃｄ４０抗体およびその使用方法
EP1945260B1 (en) 2005-11-01 2012-10-24 Novartis AG Uses of anti-cd40 antibodies
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
NZ600075A (en) 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
KR101620642B1 (ko) 2007-11-07 2016-05-12 제넨테크, 인크. 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
WO2011008093A1 (en) 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012072814A1 (en) 2010-12-02 2012-06-07 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
DK3099709T3 (da) 2014-01-31 2020-02-03 Aimm Therapeutics Bv Midler og fremgangsmåder til fremstilling af stabile antistoffer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
AU691996B2 (en) 1998-05-28
WO1996018413A1 (en) 1996-06-20
ATE203676T1 (de) 2001-08-15
GB9425060D0 (en) 1995-02-08
NO972732L (no) 1997-06-13
JP4076230B2 (ja) 2008-04-16
MX9704372A (es) 1998-02-28
JPH10510526A (ja) 1998-10-13
NZ296161A (en) 2001-10-26
FI118918B (fi) 2008-05-15
FI972484A0 (fi) 1997-06-12
EP0806963B1 (en) 2001-08-01
AU3988495A (en) 1996-07-03
DE69522012D1 (de) 2001-09-06
EP0806963A1 (en) 1997-11-19
FI972484L (fi) 1997-06-12
DE69522012T2 (de) 2002-04-25
CA2207779A1 (en) 1996-06-20
CA2207779C (en) 2009-10-06
NO318587B1 (no) 2005-04-11

Similar Documents

Publication Publication Date Title
NO972732L (no) Karsinombehandling
DK0877734T3 (da) Quinolin- og quinazolinforbindelser, der er egnede i terapi
TR200000726T2 (tr) Budesonid ve formoterol'ün yeni kullanımı.
MXPA02001726A (es) Celda de combustible y placa bipolar para utilizarse con la misma.
ATE209366T1 (de) Elektrochrome oder photoelektrochrome vorrichtung
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
ES292314U (es) Un articulo sanitario
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
DE59008501D1 (de) Neue, stickstoffhaltige Titanocene und deren Verwendung.
NO912625L (no) Betongstein belagt med kopolymerfilm, samt fremgangsmaate for fremstilling av betongsteinen.
RU95101375A (ru) Производные n-(3-аминопропил)-n-фенил-5,6,7,8-тетрагидронафталин-2-карбоксамида, их получение и применение в терапии
AU646439B2 (en) Novel retinoids
DE3766276D1 (de) Gegen abblaettern bestaendige polymerzusammensetzung, sowie beschichtung.
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
NO902532L (no) Fremgangsmaate for fremstilling av flytebro, samt flytebrofortrinnsvis fremstillet i henhold til fremgangsmaaten.
NO914720D0 (no) Somatotropiner med forandringer i alfa-spiral-3-omraadet, alfa-spiral-2-omraadekombinasjoner derav og i kombinasjon medandre mutasjoner
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
FI88228C (fi) Dielektrisk resonatorkonstruktion
DE69108396D1 (de) Hohe kolloidale Kapazitätsekundärbatterie, Kolloidelektrolyt und dessen Verwendung, sowie deren Herstellungsverfahren.
TR200002939T2 (tr) Paroksetin maleat
ES8504419A1 (es) Procedimiento para la sensibilizacion al calor de dispersiones acuosas de polimero.
DE59400924D1 (de) Beta-Hydroxyoximether und bei Raumtemperatur mit beta-Hydroxyoximethern vernetzbare Dispersionen oder Lösungen
AU8136398A (en) Sheet aligning device and sheet treating device provided with the same
Marshall The more things change...: social reproduction and socialist-feminist theory
KR940018863U (ko) 온, 난방 장치를 구비한 식탁

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees